Welcome to our dedicated page for Genfit news (Ticker: GNFT), a resource for investors and traders seeking the latest updates and insights on Genfit stock.
GENFIT S.A. (GNFT) reports clinical-development and licensing updates tied to liver-disease programs. Company news has included the exclusive licensing of elafibranor, a PPAR alpha and delta agonist evaluated for primary biliary cholangitis, and partnership terms assigning development and commercialization rights with Ipsen. Updates also cover the licensing of SRT-015, an ASK1 inhibitor candidate, for an injectable formulation directed at acute liver disease, including acute-on-chronic liver failure.
Recurring coverage centers on therapeutic-program ownership, partner responsibilities, milestone and royalty structures, equity investments connected to collaborations, and foreign-issuer corporate communications for the company’s Nasdaq and Euronext-listed securities.
Summary not available.
Ipsen has secured global rights to develop and commercialize GENFIT's innovative treatment, elafibranor, aimed at Primary Biliary Cholangitis (PBC). The agreement provides GENFIT with an upfront payment of €120 million and potential milestone payments totaling €360 million, alongside royalties up to 20%. Ipsen will also acquire an 8% equity stake in GENFIT through a €28 million investment. The Phase III trial, ELATIVE™, is ongoing, with top-line data expected in early 2023, presenting a significant opportunity for both companies in addressing unmet medical needs in liver diseases.